The pharmacokinetics of lamivudine in patients with impaired hepatic function.
OBJECTIVE
This study was designed to evaluate the effect of hepatic impairment on the pharmacokinetics of lamivudine.


METHODS
Sixteen patients not infected with hepatitis B virus or human immunodeficiency virus who had hepatic impairment due to liver cirrhosis were assigned to moderately or severely impaired groups by clinical signs/symptoms, 14C-aminopyrine metabolic activity and caffeine clearance and compared with eight healthy controls. Following a 300-mg dose of lamivudine, blood and urine samples were taken for drug assay.


RESULTS
Lamivudine was well tolerated in patients with hepatic impairment. There were no statistical differences in overall lamivudine exposure (in terms of AUC or Cmax) or other major pharmacokinetic parameters i.e. CLR, tmax and t1/2, between healthy control subjects and patients with moderate or severe hepatic impairment.


CONCLUSIONS
Hepatic impairment does not warrant dose modification of lamivudine based on this single-dose pharmacokinetic study.
Department of Clinical Pharmacology, Glaxo Wellcome Research and Development Ltd. Middlesex, UK. MAJ4852@ggr.co.uk
M A
MA
Johnson
J
J
Horak
P
P
Breuel
D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D002110:Caffeine / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D019259:Lamivudine / Q000493:pharmacokinetics*; D008103:Liver Cirrhosis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D019380:Anti-HIV Agents; D019259:Lamivudine; D002110:Caffeine